Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Free Cash Flow (2023 - 2025)

Bioharvest Sciences has reported Free Cash Flow over the past 3 years, most recently at -$6.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 17.71% year-over-year to -$6.3 million; the TTM value through Dec 2025 reached -$9.6 million, down 0.65%, while the annual FY2025 figure was -$9.6 million, 0.65% down from the prior year.
  • Free Cash Flow was -$6.3 million for Q4 2025 at Bioharvest Sciences, down from -$1.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $750000.0 in Q2 2024 and bottomed at -$7.7 million in Q4 2024.
  • The 3-year median for Free Cash Flow is -$1.3 million (2024), against an average of -$2.2 million.
  • The widest YoY moves for Free Cash Flow: up 45.21% in 2025, down 215.2% in 2025.
  • Over 3 years, Free Cash Flow stood at -$2.7 million in 2023, then tumbled by 183.61% to -$7.7 million in 2024, then rose by 17.71% to -$6.3 million in 2025.
  • The last three reported values for Free Cash Flow were -$6.3 million (Q4 2025), -$1.7 million (Q3 2025), and -$864000.0 (Q2 2025) per Business Quant data.